The delivery platform is available for out-licensing, either on an exclusive basis or a field-specific application. The platform has shown the ability to deliver a therapeutic compound directly into the cytoplasm. This makes the Fusogenix platform a compelling option for the effective delivery of small molecules, peptides, and siRNA as functional pharmaceuticals.

Avian System for Evaluating Therapeutics (ASET) Platform

For pharmaceutical and biotech companies with libraries of compounds, Innovascreen offers an effective and robust partnership opportunity. By using the ASET platform, Innovascreen can analyse the full library to indentify the best candidates at a fraction of the cost in a fraction of the time of standard preclinical tests. Using proprietary imaging technology, the outputs are useful for presentation and publications, including movies of the compound as it moves through the testing process.

Download ASET Platform Factsheet

For Business Development Inquiries, Please contact Jeff Skinner, Director Business Development at jeff.skinner@innovascreen.com.